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To the Editor: We read with interest the article by Dr P Liss
et al.1 They reported results contrary to that of our
RECOVER study and recent meta-analysis, which revealed
a lower incidence of contrast induced nephropathy (CIN) in
iodixanol than in ioxaglate users.2,3 We have some comments
and queries.
First, this different result may be attributed to the study
scheme itself. Our RECOVER study was a prospective
randomized controlled trial, but Dr P Liss’s was a retro-
spective study with many compounding factors influencing
the results.
Second, they did not present the most important risk
factors of CIN, basal serum creatinine and contrast dose.
They only briefly mentioned the data of 14% of patients
(8100 among 57 925 patients) and these data were recorded
in only a restricted period of 2005. They just reported the
mean and median values without depicting P-values.
Third, and most importantly, baseline characteristics of
the two groups were significantly different. The risk factors of
CIN – age, proportion of patients with diabetes, patients with
STEMI, unstable angina, proportion of patients receiving
PCI, previous renal failure, and previous dialysis – were
significantly different between the two groups.
We think that previous renal failure and previous dialysis
were the most critical determinants of developing CIN and
factors affecting clinical outcomes – re-hospitalization with a
renal failure and start of dialysis after angiography. These
were much more in the iodixanol group, which, we think,
might influence the result of poorer clinical outcomes of
iodixanol users.
We completely disagree with Dr P Liss et al. We think that
larger-scale long-term clinical data are necessary for solving
the important issue of which contrast medium is renal
protective.
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We thank Jo et al.1 for their thoughtful comments on our
manuscript. Indeed the outcome of our study sheds new
light on to the debate, which class of contrast media may
be best for avoiding renal failure.
Jo et al. feel that our study design, that is being
retrospective, may partly explain the outcome. Of course
the value of a study critically depends upon the design.
Optimal outcome can be expected for prospective rando-
mized studies with very large sample sizes. In this sense, all
studies focussing on contrast media and kidney function in
humans must be considered with caution: for instance, the
RECOVER2 study by Jo and co-workers, and the NEPH-
RIC3 study by Aspelin and co-workers were prospective
studies with 129 and 300 patients, respectively. In the study
discussed here,4 57 925 patients were evaluated on a
retrospective basis. Retrospective studies are widely in
use and provide valuable insight, such as the effectiveness
of vaccinations, only to mention one.
Jo et al. point out that values for basal creatinine and
the dose of contrast media were not available for all
patients. We agree that this is a drawback. Only since
2005 does the register include these data. Thus, we
analyzed these data in 8100 patients. As stated in the
publication, there were no significant differences in
828 Kidney International (2007) 71, 827–830
l e t t e r t o t h e e d i t o r :
